Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
Companies›Healthcare›Healthcare›Healthcare Equipment & Supplies
NSE:NURECA

NURECA LIMITED

Healthcare › Healthcare Equipment & Supplies
₹310.00
at close · 27 Oct 2026
▲ 1.00 (+0.32%)

Latest filings

  1. Newspaper copies filed for September 2026 results · Compliance
  2. Nureca Q2 FY27 revenue up 55% at Rs 58.53 cr, highest in 20 quarters · Compliance
  3. Q2 FY27: Revenue up 55% YoY to Rs 585M, PAT at Rs 40.5M · Results
All filings ↓
Ask Nexa about NURECA LIMITED

Snapshot

What the business is, and whether it's a good one at a fair price.

A Healthcare Equipment & Supplies company listed on NSE and BSE, reporting revenue of ₹187 Cr over the trailing twelve months.

Market Cap
₹296 Cr
P / E (TTM)
60.7×
EV / EBITDA
21.8×
Div Yield
—
Growth
-7.2%▼
Revenue 5y CAGR
PAT -46.2% · EBITDA -33.6%
Quality
1.3%·
ROCE (5y median)
ROE 0.4% (5y median) · margin 5.6%
Leverage
0.00·
Debt / Equity · low
Net cash ₹0.75 Cr
Revenue FY21→FY26
0.7×▼
Margin −20.3 pts
₹213 Cr → ₹147 Cr
Cash conversion
-0.18×▼
Operating cash ÷ profit · 5 yrs
₹-7 Cr on ₹38 Cr
Moves on a normal day
1.51%·
Median daily move
Last 267 sessions · the yardstick for filing-day moves
Where it sits among 16 Medical Equipment & Supplies peersBar = share of peers beaten · tick = industry median · latest reported figures
P/E (TTM)#13/16
P/B#4/11
ROCE#15/17
ROE#10/11
Debt / Equity#3/11
EBITDA margin#9/11
Revenue growth#6/13
Profit growth#2/10

Scorecard

Measured from the filed financials, judged against its Medical Equipment & Supplies peers · as of FY26 — not investment advice

Strengths
Debt at 0.00× equity
lower than 80% of its 11 Medical Equipment & Supplies peers
Concerns
Revenue shrinking over 5 years (−7% a year)
Profit shrinking over 5 years (−46% a year)
Returns on capital 1.3% (5-year median)
#15 of 17 in Medical Equipment & Supplies on the latest reported figures · down from 38.3% in FY21
Over 5 years it reported ₹38 Cr of profit and an operating cash outflow of ₹6.87 Cr — -0.18×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 125 days of cash tied up

Charts

How has the market priced it — with filings on the timeline?

NURECA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from NURECA LIMITED's filed financials and exchange disclosures

What does NURECA LIMITED do?

NURECA LIMITED is a Healthcare Equipment & Supplies company listed on NSE and BSE, trading under the symbol NURECA.

Is NURECA LIMITED profitable?

Yes. Over the trailing twelve months NURECA LIMITED reported a net profit of ₹5.15 Cr on revenue of ₹187 Cr.

Does NURECA LIMITED pay a dividend?

Not in the latest reported year — NURECA LIMITED's dividend payout for FY26 was nil.

Is NURECA LIMITED debt-free?

On a net basis, yes. It reported borrowings of ₹0.72 Cr on its 31 Mar 2026 balance sheet, but holds ₹0.75 Cr more cash than debt.

Is NURECA LIMITED expensive compared with its peers?

On trailing P/E, NURECA LIMITED ranks 13 of 16 in Medical Equipment & Supplies — cheaper than 20% of them, against an industry median of 21.0×. This is a position, not a valuation judgement.

How much does the NURECA LIMITED share price move in a day?

On a typical session NURECA LIMITED moves 1.51% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.

Where can I track NURECA LIMITED's announcements?

Every NSE and BSE filing by NURECA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.